This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D81.5 (purine nucleoside phosphorylase deficiency) | OMIM: 613179 | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | PNP deficiency, Purine nucleoside phosphorylase deficiency, NP deficiency, Immunodeficiency due to purine nucleoside phosphorylase deficiency |
| C. Adult onset | Likelihood of first onset in adulthood very low — mostly manifests in infancy to early childhood, but in the partial deficiency form, cases first diagnosed in late childhood or rarely in adolescence have been reported; only a very small number of cases worldwide have had diagnosis delayed into adulthood. |
| 1. History | 1975 Giblett et al. first reported absent PNP enzyme activity in a child with T-cell immunodeficiency → subsequent elucidation of the mechanism linking purine metabolism and selective T-cell deficiency → the second purine metabolic enzyme deficiency immunodeficiency discovered, after ADA deficiency. |
| 2. Causes | Pathogenic variants of the NP gene on chromosome 14 (14q13.1) → loss of PNP enzyme activity → accumulation of deoxyguanosine and deoxyinosine → excess dGTP → selective T-cell toxicity and death. |
| 3. Genetics | Autosomal recessive (AR). NP gene (14q13.1), 6 exons, homotrimeric enzyme. Many missense, nonsense and splicing variants reported. Mild phenotype in partial deficiency. |
| 4. General epidemiology | About 100 cases reported worldwide. Incidence estimated at about 1/1,000,000. Equal in males and females. Number of patients in Korea unconfirmed but estimated at around a few. |
| 5. Pathophysiology | PNP deficiency → excessive dGTP accumulation → RNR inhibition → impaired DNA synthesis → T-cell-specific death. Neurologic dGTP toxicity and dysfunction of autoimmunity-regulating T cells are also involved. |
| 6. Symptoms | Recurrent opportunistic infections (PCP, CMV, Candida), failure to thrive, neurodevelopmental delay, autoimmunity (AIHA, ITP, SLE-like), increased risk of malignancy. |
| 7. Signs | Decreased T cells (CD3+↓), normal immunoglobulins, absent erythrocyte PNP activity, elevated urine/serum deoxyguanosine, white matter abnormalities on brain MRI. |
| 8. Screening | TREC-based newborn screening, erythrocyte PNP enzyme activity, early genetic testing based on family history. |
| 9. Diagnosis | Lymphocyte analysis (flow cytometry), PNP enzyme activity (erythrocytes), metabolite quantification (urine), NP gene sequencing, neurologic evaluation. |
| 10. Treatment | HSCT (curative), prophylactic TMP-SMX, antifungals and IVIG, live vaccines contraindicated. Gene therapy (clinical trial stage). Rehabilitation for neurologic complications. |
| 11. Prognosis | Over 80% survival with early HSCT. Neurologic complications partially improve after transplantation. Some autoimmune phenomena persist. Poor prognosis with delayed diagnosis. |
| 12. Prevention | Genetic counseling, PGT/prenatal genetic testing, newborn TREC screening, infection prevention, live vaccines contraindicated, use of irradiated blood products. |
| 13. References | Giblett ER et al. Purine-nucleoside phosphorylase deficiency in a child with severely defective T-cell immunity … and 9 other papers |
The history of purine nucleoside phosphorylase (PNP) deficiency begins at the intersection of immunology and biochemistry. In 1972, Dr. Eloise Giblett discovered that erythrocyte adenosine deaminase (ADA) activity was absent in a child with severe combined immunodeficiency (SCID), revealing to the world the groundbreaking fact that a specific enzyme deficiency can cause immunodeficiency. This discovery led to the recognition that the purine metabolic pathway is critically important for immune function and stimulated the search for similar metabolic enzyme defects.
In 1975, Giblett, together with colleagues Anderson, Cohen, Pollara and Meuwissen, published a historic paper in Lancet. This study reported for the first time that erythrocyte PNP enzyme activity was completely absent in a child characterized by recurrent opportunistic infections and T-lymphocyte deficiency. Particular attention was drawn to the fact that, unlike ADA deficiency, B-lymphocyte function is relatively preserved in PNP deficiency, resulting in a T-cell-selective immunodeficiency. This discovery was the second immunodeficiency cause identified among purine metabolic enzyme deficiencies and confirmed the importance of the purine salvage pathway in the context of clinical immunology.
From the late 1970s through the 1980s, understanding of the molecular mechanism of PNP deficiency advanced. Cohen et al. systematically elucidated the mechanism whereby, in PNP deficiency, deoxyguanosine accumulates within cells and is converted to deoxy-GTP (dGTP), which is toxic to T cells. In the 1980s, protein structure studies showing that PNP has a homotrimer structure were published, and the gene encoding human PNP (NP) was found to be located on the long arm of chromosome 14 (14q13.1). Along with elucidation of the mechanism at the molecular level, cases began to accumulate worldwide, and the fact that some patients have neurologic complications (developmental delay, spastic paralysis) was also confirmed through clinical records.
In the 1990s, with advances in recombinant DNA technology and molecular diagnostics, various pathogenic variants of the NP gene began to be identified. Various types of gene variants, including missense, nonsense and splicing variants, were reported, and it became clear that the severity of the clinical phenotype can differ depending on the type of variant and whether residual enzyme activity remains. Hematopoietic stem cell transplantation (HSCT) was attempted as a treatment to restore immune function in PNP deficiency, and successful transplant cases began to be reported. However, it was also recognized in this period that HSCT does not completely reverse neurologic complications that have already occurred.
In the 21st century, with the introduction of next-generation sequencing (NGS) technology, discovery of new NP gene variants and studies of genotype-phenotype correlations became active. At the same time, TREC (T cell receptor excision circle)-based testing was developed and disseminated as newborn screening for T-cell immunodeficiencies including PNP deficiency. In terms of gene therapy, PNP deficiency is attracting attention as a research target for hematopoietic stem cell gene correction using lentiviral vectors, and the possibility of T-cell reconstitution has been demonstrated in preclinical studies. Currently, PNP deficiency is registered as OMIM 613179 (MIM #613179) and is also managed as a separate rare disease entry in Orphanet (ORPHA:753).
The root cause of PNP deficiency is pathogenic variants of the NP gene, which encodes the purine nucleoside phosphorylase (PNP) enzyme. The NP gene is located at position 13.1 on the long arm of chromosome 14 (14q13.1) and consists of 6 exons. When homozygous or compound heterozygous pathogenic variants occur in this gene, PNP enzyme activity is markedly reduced or completely lost.
PNP plays a key role in the purine salvage pathway. Using inorganic phosphate (Pi), this enzyme phosphorolyzes nucleosides (inosine, guanosine, deoxyinosine, deoxyguanosine, etc.) into the corresponding nucleobases (hypoxanthine, guanine, etc.) and ribose-1-phosphate or deoxyribose-1-phosphate. This reaction is a central step in the catabolic pathway of purine nucleosides; normally, surplus purine nucleosides are broken down and converted into reusable purine bases and sugar phosphates.
When the PNP enzyme is deficient, its substrate nucleosides, particularly deoxyguanosine and deoxyinosine, accumulate within cells. Accumulated deoxyguanosine is sequentially phosphorylated by deoxyguanosine kinase and nucleoside diphosphate kinase to form deoxy-GTP (dGTP). This excessive intracellular accumulation of dGTP is the direct cause of immunodeficiency. dGTP acts as an allosteric inhibitor of ribonucleotide reductase (RNR), and inhibition of RNR causes depletion and imbalance of the deoxyribonucleotide pool (dNTP pool) essential for DNA synthesis, leading to cell division arrest and death.
T lymphocytes and their precursors are particularly sensitive to this toxicity, because T cells have high deoxyguanosine kinase activity and rapidly accumulate dGTP, while their ability to break it down or bypass it is relatively weak. In contrast, B lymphocytes are relatively resistant to this toxicity and are numerically preserved, which accounts for the 'T−B+ immunodeficiency' pattern that is the clinical hallmark of PNP deficiency. However, without T-cell help, B cells have incomplete antibody responses to T-cell-dependent antigens, so a functional immunodeficiency exists.
The effects of PNP deficiency also appear in the central nervous system. Because brain neurons and glial cells depend on the purine salvage pathway, dGTP accumulation is presumed to cause nervous system dysfunction. It has also been hypothesized that in PNP deficiency the metabolism of adenosine and deoxyadenosine is indirectly affected, so that changes in adenosine receptor signaling may contribute to additional neurotoxicity and autoimmune predisposition. In this way, PNP deficiency goes beyond a simple enzyme deficiency and has complex effects on the immune system, nervous system and autoimmune regulatory function through disturbance of purine metabolism as a whole.
PNP deficiency follows an autosomal recessive (AR) mode of inheritance. To be affected, a person must inherit one pathogenic variant allele from each parent and be a homozygote or compound heterozygote. Carrier parents mostly have normal PNP activity and are asymptomatic. The probability that a sibling is affected is 25% (with each pregnancy).
The causative gene NP (or PNP, Gene ID: 4860) is located on chromosome 14q13.1 and consists of 6 exons spanning about 10 kb of the genome. The mature mRNA is about 1,200 bp and encodes a 32 kDa monomer of 289 amino acids. Functional PNP protein has a homotrimer structure in which three monomers combine to form three active sites. Because a variant in a single monomer can disturb the structure and function of the entire trimer, a single missense variant can result in complete loss of enzyme activity.
The types of pathogenic NP gene variants reported in the literature to date are diverse. Missense variants are the most common and impair enzyme activity by altering residues of the active site or trimer interface. In particular, variants of residue Arg234 (R234) have been reported in several families. Nonsense variants and small insertions/deletions (frameshift variants) create premature stop codons or disrupt the open reading frame, causing loss of function (loss-of-function). Splice-site variants disturb mRNA splicing, causing exon skipping or intron retention.
Complete deficiency (PNP activity < 1–5% of normal) causes the typical phenotype with severe T-cell immunodeficiency and neurologic complications. In contrast, some variant combinations result in partial deficiency with some residual enzyme activity, and cases have been reported in which T-cell reduction is mild and mainly only autoimmune phenomena or a mild tendency to infection is seen, without neurologic complications. Therefore, PNP deficiency should be included in the differential diagnosis even in children with mild autoimmune disease.
For molecular genetic diagnosis, targeted sequencing of the NP gene (Sanger sequencing) or next-generation sequencing (NGS) including primary immunodeficiency gene panels is used. Pathogenicity of variants is assessed according to ACMG guidelines, and biochemical confirmation by functional PNP enzyme activity measurement (erythrocytes) is essential. Familial variant analysis (confirming parental carrier status) provides the basis for genetic counseling and informs about the possibility of preimplantation genetic testing (PGT) or prenatal diagnosis in future pregnancies.
PNP deficiency is a very rare disease worldwide; since the first report in 1975, an estimated 100 or so cases have been reported in the scientific literature worldwide to date. Some researchers mention that about 100–150 patients have been reported, but because some die undiagnosed in regions lacking diagnostic infrastructure, the actual frequency may be higher. The incidence is estimated at about 1 per million births or lower, accounting for a very small fraction of the overall incidence of primary immunodeficiency (about 1/10,000).
In sex distribution, owing to autosomal recessive inheritance, males and females can be affected equally. Together with ADA deficiency, PNP deficiency is the best-studied purine metabolic enzyme deficiency immunodeficiency, but it is even rarer than ADA deficiency (about 400–500 cases worldwide). No particular concentration by race or ethnicity has been reported, but this is not unrelated to the tendency for the risk of autosomal recessive diseases in general to increase in societies where consanguineous marriage is customary.
There are no public statistics on the number of patients confirmed with PNP deficiency in Korea. Special Copayment Reduction (V111) data from the Health Insurance Review & Assessment Service (HIRA) cover the entire D81 code, making it difficult to count PNP deficiency separately. Only a few cases appear to have been reported in data from the Korea Rare Disease Information Center and the Korean primary immunodeficiency patient registry. However, diagnosis rates are expected to improve in the future with the expansion of newborn screening (TREC) and better access to molecular diagnosis.
In terms of epidemiologic significance, the ultra-rare nature of PNP deficiency is a major cause of diagnostic delay. When patients visit pediatrics or infectious diseases for recurrent infections, it can take years to reach an accurate diagnosis if primary immunodeficiency is not actively considered. There are reports that the average diagnostic delay for primary immunodeficiency patients is 5–8 years, and in a rare disease like PNP deficiency, particularly in the partial deficiency form, the clinical phenotype may be mild, making diagnostic delay even more likely. Because early diagnosis is the only opportunity to prevent neurologic complications, raising awareness of the disease among medical staff is important.
It is registered in global rare disease databases (Orphanet ORPHA:753, OMIM 613179), and data on PNP deficiency are collected and managed by international primary immunodeficiency networks such as the US PIDTC (Primary Immune Deficiency Treatment Consortium) and the European ESID (European Society for Immunodeficiencies). International collaborative research through these organizations is important for compensating for the limitations of individual studies, given the nature of rare diseases.
The pathophysiology of PNP deficiency is understood as centered on the complex toxic effects of an enzyme deficiency of the purine metabolic pathway on the immune and nervous systems. The core mechanism is selective excessive accumulation of deoxy-GTP (dGTP) within T cells, resulting in a cellular immunodeficiency in which T lymphocytes are selectively depleted.
Intracellular purine nucleoside metabolism occurs through two main pathways. One is the de novo synthesis pathway occurring in the liver, and the other is the salvage pathway that recycles surplus nucleosides in tissues. In the salvage pathway, PNP reacts inosine, guanosine, deoxyinosine and deoxyguanosine with inorganic phosphate to phosphorolyze them into nucleobases (hypoxanthine, guanine) and sugar phosphates (ribose-1-phosphate or deoxyribose-1-phosphate). Through this reaction, purine nucleosides are broken down or recycled and appropriate intracellular concentrations are maintained.
When PNP is deficient, the breakdown of deoxyguanosine is blocked. Accumulated deoxyguanosine is phosphorylated to deoxy-GMP by cytoplasmic deoxyguanosine kinase (dGK), then converted to deoxy-GDP and finally to deoxy-GTP (dGTP). The reasons this excessive dGTP accumulation is lethal to T cells are as follows. First, dGTP binds to the dGTP allosteric regulatory site of ribonucleotide reductase (RNR) and inhibits the activity of the entire enzyme. RNR is the rate-limiting enzyme that reduces ribonucleotides to deoxyribonucleotides during cell division; when it is inhibited, dCTP, dATP and dTTP synthesis are concomitantly impaired, causing overall depletion of the dNTP pool. Second, excess dGTP induces changes in mitochondrial inner membrane potential and cytochrome C release, promoting caspase-dependent apoptosis. Third, an unbalanced dNTP pool increases misincorporation in replicating DNA strands, activating the DNA damage response (DDR) and triggering cell cycle arrest and additional death signals.
Several explanations have been proposed for why B lymphocytes and other cell types are relatively resistant to dGTP toxicity. T-cell precursors and mature T lymphocytes have relatively high deoxyguanosine kinase and nucleotide kinase activity and accumulate dGTP rapidly. T cells also have low deoxynucleotidase activity and a poor ability to break down dGTP. B cells have relatively high ADA (adenosine deaminase) activity, are better able to process deoxyadenosine efficiently and protect themselves from dATP toxicity, and are known to have a stronger capacity than T cells to metabolize PNP substrates.
dGTP toxicity in central nervous system cells is cited as the main mechanism underlying the neurodevelopmental disorders, spastic quadriplegia and progressive neurologic deterioration observed in PNP deficiency patients. Because brain cells also depend on the purine salvage pathway, dGTP toxicity can occur in central nervous system cells in PNP deficiency, causing neuronal death or functional damage. In addition, changes in adenosine and guanosine concentrations in PNP deficiency may disturb adenosine receptor (adenosine receptors A1, A2A, A2B, A3) signaling and affect nervous system regulatory function. Autoimmune phenomena are understood as resulting from dysfunction of regulatory T cells (Tregs) and failure of peripheral immune regulation. When normal regulatory T cells cannot be generated in PNP deficiency, suppression of autoreactive T cells and B cells that respond to self-antigens fails, and autoimmune phenomena occur.
The clinical symptoms of PNP deficiency consist of three main axes: ① infection-related symptoms due to immunodeficiency, ② neurologic complications and ③ autoimmune phenomena; the combined appearance of these three is an important clinical feature that distinguishes it from other primary immunodeficiencies.
Recurrent and severe opportunistic infections due to T-cell deficiency are the main symptoms. Pneumocystis jirovecii pneumonia (PJP) is the most common and lethal opportunistic infection, characterized by a dry cough progressing with a subacute course, rapid respiratory rate and hypoxemia. Chest X-ray shows bilateral ground-glass opacities, and without treatment it leads to death from respiratory failure. Candidiasis appears as oral thrush, esophageal candidiasis or diaper rash and tends to recur despite antifungal treatment. Cytomegalovirus (CMV) infection can manifest as pneumonia, retinitis, hepatitis or colitis, with a high risk of systemic dissemination. Disseminated varicella due to varicella-zoster virus (VZV) is a life-threatening severe complication. Herpes simplex virus (HSV) infection can spread beyond the skin and mucosa to the esophagus, brain (herpes encephalitis) and eyes (keratitis). Bacterial infections include recurrent bacterial infections caused by pneumococcus, Haemophilus influenzae, Salmonella and others. In addition, chronic diarrhea due to cryptosporidiosis, opportunistic meningoencephalitis and the like can occur. Failure to thrive results from recurrent infections and chronic diarrhea.
One of the distinctive features of PNP deficiency is that neurologic complications accompany the immunodeficiency. Neurologic abnormalities have been reported in about 50–66% of patients. Developmental delay is the most common, with delays in motor and language development observed from infancy. Spastic paralysis (spastic diplegia or tetraplegia) appears, reflecting upper motor neuron signs due to pyramidal tract damage. In some patients, progressive neurologic deterioration is observed, with early developmental milestones achieved and then loss of function later. Abnormal EEG, seizures, eye movement abnormalities and cognitive decline are also reported. These neurologic complications often do not recover completely even after successful hematopoietic stem cell transplantation, which underscores the importance of early diagnosis and transplantation.
Because of abnormal immune regulatory function, various autoimmune diseases may be associated. Autoimmune hemolytic anemia (AIHA) is the most commonly reported, presenting with a positive direct Coombs test (DAT) together with signs of hemolysis (jaundice, pallor, reticulocytosis). Immune thrombocytopenic purpura (ITP) is also reported, with cutaneous petechiae, mucosal bleeding and decreased platelet counts. Autoimmune diseases such as systemic lupus erythematosus (SLE)-like syndrome, vasculitis and autoimmune thyroiditis have been described in PNP deficiency patients. Autoimmune phenomena may appear before the immunodeficiency, or in mild partial PNP deficiency may be the main symptoms, making diagnosis difficult.
The clinical signs of PNP deficiency are divided into physical examination findings and laboratory findings, and diagnosis is approached by combining both.
On assessment of general condition, signs of failure to thrive are prominent. Weight and height are below the 3rd percentile on growth charts or drop markedly from previous percentiles. Oral thrush does not respond to treatment or recurs persistently. Persistent candidal lesions of the skin and perianal area may appear. With complicating pneumonia, wheezes and crackles on auscultation, accessory muscle use during breathing and nasal flaring are observed. Characteristically, despite recurrent infections, lymph nodes are small or not palpable (lymph node hypoplasia). This is because, in the absence of T-cell-dependent immune responses, germinal center formation within lymph nodes and reactive lymph node enlargement do not occur. On neurologic examination, spastic paralysis (increased muscle tone, hyperreflexia of deep tendon reflexes, positive Babinski sign), delayed developmental milestones and delayed language development are observed. With complicating autoimmune hemolytic anemia, conjunctival pallor and scleral icterus may appear. Hepatosplenomegaly may result from recurrent infections, viral infections (CMV, EBV) and autoimmune processes.
On peripheral complete blood count (CBC), decreased absolute lymphocyte count (ALC) is the most important initial clue. In normal infants, ALC is 3,000–9,000/μL, but in PNP deficiency it is markedly lower, falling below 1,000/μL in severe cases. When accompanied by autoimmune hemolytic anemia, decreased hemoglobin, reticulocytosis and elevated LDH appear. Analysis of lymphocyte subsets by flow cytometry shows marked reduction of all CD3+, CD4+ and CD8+ T cells, with CD19+ B cells normal or relatively increased and NK cells (CD16+CD56+) variable (normal to decreased). Serum immunoglobulins (IgG, IgA, IgM) are within the normal range or elevated, but specific antibody responses to T-cell-dependent antigens are impaired, so a functional antibody deficiency exists. T-cell function tests (proliferative responses to mitogens such as PHA) show marked impairment. Measurement of erythrocyte PNP enzyme activity shows marked reduction to less than 5% of normal (complete deficiency) or a range of 5–30% (partial deficiency). Plasma and urine concentrations of deoxyguanosine, deoxyinosine and inosine are markedly higher than normal. Brain MRI may show white matter abnormality, cerebral atrophy and delayed myelination. Autoimmune findings may include a positive direct Coombs test (DAT), antinuclear antibodies (ANA), anti-dsDNA antibodies and thrombocytopenia. TREC analysis shows a marked reduction, which is the basis for detecting this disease on newborn screening.
Newborn screening for severe T-cell immunodeficiencies including PNP deficiency aims to prevent infectious complications and minimize neurologic damage through early diagnosis before symptom onset.
T cell receptor excision circles (TREC) testing is currently the most standard newborn screening method for T-cell deficiency disorders. TRECs are small circular DNA fragments generated during TCR gene rearrangement as T cells mature in the thymus, and are a direct surrogate marker of thymic activity and new peripheral T-cell generation (thymopoiesis). In PNP deficiency, TRECs are markedly reduced or fall to unmeasurable levels because of depletion of the T cells themselves. TREC measurement is performed by real-time PCR on dried blood spots (DBS) collected 24–48 hours after birth, and accurate quantification is possible with only a few microliters of blood. In the United States, TREC-based SCID/T-cell deficiency newborn screening has been mandatory in all 50 states since 2010, and adoption is expanding in several European countries. In Korea, TREC-based newborn screening has not yet been designated as a mandatory national screening item, but related research and policy discussions are under way.
In high-risk families with an affected sibling or confirmed carrier parents, active screening should begin immediately after birth. Specifically, this includes ① peripheral blood absolute lymphocyte count and T/B/NK cell fractions (flow cytometry) within the first 2 weeks of life, ② measurement of erythrocyte PNP enzyme activity, and ③ targeted NP gene variant analysis. When the causative variant in the family has been identified, the diagnosis can be quickly confirmed by targeted analysis of the variant site.
When parents are confirmed carriers, genetic counseling before the next pregnancy offers the options of prenatal diagnosis (chorionic villus sampling or amniocentesis) or preimplantation genetic testing (PGT). PGT is a method of performing genetic analysis at the embryo stage during in vitro fertilization to select out affected embryos before implantation, and can prevent the birth of an affected child without termination of pregnancy.
In symptomatic infants, measuring erythrocyte PNP enzyme activity as primary screening is a relatively simple and rapid way to check for PNP deficiency. This test can be performed in a standard biochemistry laboratory by colorimetric assay or spectrophotometry. Even if TREC results are positive, additional PNP enzyme activity screening may be considered in children with autoimmune phenomena or neurologic abnormalities, which helps detect the partial deficiency form of PNP deficiency.
Diagnosis of PNP deficiency proceeds stepwise through clinical suspicion, biochemical verification and molecular genetic confirmation. Active differentiation is required particularly in children in whom immunodeficiency, neurologic abnormalities and autoimmune phenomena appear together.
Measuring the absolute lymphocyte count (ALC) on complete blood count (CBC) is the first step. Referral for flow cytometry is recommended when ALC < 2,500/μL (infants) or below the age-specific lower limit of normal. Flow cytometry measures the absolute numbers and fractions of CD3+, CD4+ and CD8+ T cells and also analyzes CD19+ B cells and CD16+/CD56+ NK cells. The typical pattern of PNP deficiency is markedly reduced T cells (CD3+) with normal or increased B cells (T−B+ NK+/− pattern).
A lymphocyte proliferation assay measures T-cell proliferative responses to stimulation with mitogens (PHA, anti-CD3) and antigens (tetanus toxoid, Candida antigen). In PNP deficiency, these responses are markedly impaired, which is important for confirming functional deficiency beyond a simple reduction in T-cell numbers.
On quantification of IgG, IgA and IgM, PNP deficiency is characterized by normal or elevated findings. However, if an insufficient antibody response is confirmed by measuring titers of specific antibodies after vaccination (anti-tetanus, anti-HBs, etc.), a functional humoral immunodeficiency can be demonstrated.
This is the biochemical standard test for diagnosing PNP deficiency. PNP enzyme activity is measured in erythrocyte lysates by colorimetric or radioisotope labeling methods. Less than 5% of normal is classified as complete deficiency and 5–30% as partial deficiency. In carrier parents, enzyme activity is often 40–60% of normal.
Concentrations of deoxyguanosine, deoxyinosine, inosine and guanosine in plasma and urine are measured by high-performance liquid chromatography (HPLC) or mass spectrometry (LC-MS/MS). Elevation of plasma and urine deoxyguanosine concentrations above detectable levels supports the diagnosis.
The causative variant is confirmed by NP gene sequencing (targeted Sanger sequencing or NGS panel, whole exome sequencing WES). Variant classification is performed according to ACMG guidelines, and the clinical significance of the variant is assessed in conjunction with functional PNP enzyme activity.
Brain MRI (to check for white matter abnormalities, cerebral atrophy and delayed myelination), EEG and developmental assessment are performed. An autoimmune panel checks the direct Coombs test (DAT), platelet count, ANA, anti-dsDNA antibodies, antiphospholipid antibodies, thyroid autoantibodies and others.
Differentiation is needed from ADA deficiency (T−B−NK− SCID, rickets-like findings on bone X-ray), RAG1/RAG2 deficiency (T−B−NK+ SCID), JAK3 deficiency (X-linked SCID-like, T−B+NK− pattern) and DiGeorge syndrome (22q11.2 deletion, with cardiac and parathyroid abnormalities). Distinction is also needed from MHC class I and class II deficiency (normal immunoglobulins but some T cells present).
Treatment of PNP deficiency is divided into curative treatment for immune reconstitution and prevention of complications and supportive care. Given the irreversibility of neurologic complications, starting treatment as early as possible is key to prognosis.
To date, this is the only established curative therapy for restoring T-cell immune function in PNP deficiency. Transplanting hematopoietic stem cells from a normal donor reconstitutes immune cells that produce the PNP enzyme normally, resolving dGTP toxicity and restoring T-cell immunity. As HSCT conditioning, myeloablative or reduced-intensity regimens based on busulfan, fludarabine and cyclophosphamide are used. In PNP deficiency, the risk of graft rejection is low because of T-cell deficiency, so reduced-intensity conditioning is also considered, but balancing sufficient space for engraftment against GVHD prevention is important. An HLA-matched sibling donor is ideal; if unavailable, transplantation from an unrelated HLA-matched donor or a haploidentical donor is also attempted. When HSCT succeeds and immune function is restored, recurrent infections decrease markedly and survival improves.
In ADA deficiency, PEG-ADA enzyme replacement therapy, in which bovine ADA is conjugated to polyethylene glycol (PEG), is established, but a similar PEG-PNP therapy for PNP deficiency has not yet been clinically established. However, the possibility that supplying exogenous PNP enzyme could alleviate dGTP toxicity is being examined in preclinical studies. In the direction of substrate reduction, methods of inhibiting intracellular phosphorylation of deoxyguanosine (dGK inhibitors, etc.) have been proposed theoretically but have not reached the stage of clinical application.
Gene therapy research introducing the normal NP gene into the patient's autologous CD34+ hematopoietic stem cells using lentiviral or retroviral vectors is under way. Autologous gene correction has the advantage of enabling permanent immune reconstitution without the risk of GVHD. Precise gene correction using CRISPR/Cas9-based gene editing technology is also being examined at the preclinical research stage.
Prevention of opportunistic infections before and after HSCT is essential. For Pneumocystis jirovecii prophylaxis, trimethoprim-sulfamethoxazole (TMP-SMX, TMP 5 mg/kg per day, 3 times a week) is given continuously. If TMP-SMX is not tolerated, it is replaced by atovaquone or inhaled pentamidine. For antifungal prophylaxis, fluconazole or itraconazole is given. For prevention and pre-emptive therapy of CMV infection, a system of regular CMV PCR monitoring and ganciclovir/valganciclovir administration is established. IVIG is given regularly every 3–4 weeks to maintain the serum IgG trough level at 700–800 mg/dL or above. Live vaccines (BCG, MMR, varicella, rotavirus, oral polio, etc.) are absolutely contraindicated. For transfusions, irradiated and CMV-negative or leukocyte-filtered (leukodepleted) blood products must always be used. In patients with neurologic complications, early physical therapy, speech therapy and cognitive rehabilitation are started.
The prognosis of PNP deficiency is determined by the timing of diagnosis, whether and when hematopoietic stem cell transplantation is performed, and the presence and degree of neurologic complications. Overall, the prognosis is very poor without treatment, and early HSCT is the only way to greatly improve survival and quality of life.
Untreated natural course: If left untreated, most patients die from recurrent opportunistic infections in infancy to early childhood (within a few years of birth). Pneumocystis pneumonia, disseminated CMV infection, disseminated varicella and the like act as fatal complications. Neurologic deterioration progresses, in some cases to a state of complete disability.
Prognosis after HSCT: When HSCT is performed successfully early, immune function is restored, recurrent infections decrease markedly and long-term survival is possible. In large primary immunodeficiency cohort studies, 3–5-year survival after HLA-matched sibling donor HSCT is 85–90% or higher, and survival of 70–85% has also been reported after unrelated donor HSCT. When immune reconstitution is complete, prophylactic antibiotics and IVIG are gradually discontinued, and live vaccination also becomes possible. However, even after successful HSCT, long-term monitoring for transplant-related complications such as graft-versus-host disease (GVHD) and post-transplant lymphoproliferative disorder (PTLD) is needed.
Prognosis of neurologic complications: Even when HSCT is performed successfully, neurologic complications that have already occurred (spasticity, developmental delay, cognitive decline) often do not recover completely, and in many cases progression stops or there is only partial improvement. This is the most important limiting factor in the prognosis of PNP deficiency and is why early transplantation before neurologic damage occurs is critically important. Cases have been reported in which patients diagnosed before symptom onset through newborn TREC screening achieved successful immune reconstitution without neurologic complications, supporting the importance of early screening.
Course of autoimmune phenomena: Autoimmune phenomena such as autoimmune hemolytic anemia and immune thrombocytopenic purpura often improve with immune reconstitution after HSCT, but in some patients they may persist or recur. Until HSCT, they are managed with immunosuppressive or immunomodulatory treatment such as steroids, IVIG and rituximab.
Long-term follow-up indicators: After successful HSCT, monitoring continues regularly for T-cell numbers and function, serum immunoglobulins, vaccine antibody titers, neurologic function, growth and development, endocrine function (gonadal function related to myelotoxic conditioning) and malignancy (particularly EBV-related PTLD).
Prevention of PNP deficiency is organized into primary prevention to prevent the occurrence of the disease, secondary prevention through early diagnosis and infection prevention, and tertiary prevention to minimize complications.
Because the parents of a child affected by PNP deficiency are carriers, the birth of an affected child is expected with a 25% probability in the next pregnancy. The following options are discussed with a genetic counseling specialist. ① Preimplantation genetic testing (PGT): combined with in vitro fertilization (IVF), NP gene variant analysis is performed at the fertilized egg stage to select out affected embryos. ② Prenatal genetic diagnosis: fetal DNA analysis by chorionic villus sampling (11–14 weeks) or amniocentesis (15–20 weeks). ③ Accepting the risk of being affected, giving birth and preparing for early treatment: some families choose to prepare for early treatment instead of reproductive options for moral or religious reasons. In this case, immune evaluation and HSCT preparation are planned to start immediately after birth.
TREC-based newborn screening detects T-cell deficiency early before symptom onset so that immediate linkage to treatment can occur. After diagnosis is confirmed, prevention of opportunistic infections during the period of HSCT preparation is essential. Pneumocystis prophylaxis with TMP-SMX, antifungal administration, regular IVIG supplementation, provision of an isolated environment and absolute contraindication of live vaccines are the key preventive measures. Siblings and close-contact family members should not receive oral polio vaccine (OPV), varicella vaccine or rotavirus vaccine, and direct contact with the patient should be avoided.
A long-term follow-up system after HSCT is established to regularly evaluate full recovery of immune function, GVHD, PTLD, autoimmune recurrence, neurologic function, endocrine function, and growth and development. In patients with neurologic complications, early rehabilitation (physical therapy, speech therapy, cognitive therapy) is started and long-term neurologic follow-up is maintained. Psychosocial support for the family and guidance on patient organizations (Korean primary immunodeficiency patient association, PIDTC, Jeffrey Modell Foundation, etc.) are also important elements of tertiary preventive management. For those who survive into adulthood, transition care to an adult immunology specialist is planned.
Giblett ER, Ammann AJ, Wara DW, Sandman R, Diamond LK. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet. 1975;1(7914):1010–1013. DOI: 10.1016/S0140-6736(75)91950-9. PMID: 48676.
Cohen A, Gudas LJ, Ammann AJ, Staal GE, Martin DW Jr. Deoxyguanosine triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency. Journal of Clinical Investigation. 1978;61(5):1405–1409. DOI: 10.1172/JCI109058. PMID: 659586.
Markert ML. Purine nucleoside phosphorylase deficiency. Immunodeficiency Reviews. 1991;3(1):45–81. PMID: 1931467.
Grunebaum E, Cohen A, Roifman CM. Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies. Current Opinion in Allergy and Clinical Immunology. 2013;13(6):630–638. DOI: 10.1097/ACI.0000000000000001. PMID: 24145561.
Hashem H, Bhatt S, Lakshmanan A, et al. Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency with two novel mutations: a case report and review of literature. Hematology/Oncology and Stem Cell Therapy. 2024. DOI: 10.1080/16078454.2024.2445404.
Dror Y, Grunebaum E, Dalal I, et al. Purine nucleoside phosphorylase deficiency associated with a dysregulated immune system and inflammatory bowel disease. Journal of Pediatrics. 2004;145(5):686–690. DOI: 10.1016/j.jpeds.2004.07.029. PMID: 15520775.
Cassidy JT, Petty RE. Pediatric Rheumatology. 5th ed. Elsevier; 2005. Chapter on Immunodeficiency and Autoimmunity. pp. 580–610.
Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology. 2018;38(1):96–128. DOI: 10.1007/s10875-017-0464-9. PMID: 29226301.
Moratto D, Gaspar HB, Forino C, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980–2009: an international collaborative study. Blood. 2011;118(6):1675–1684. DOI: 10.1182/blood-2010-11-319376. PMID: 21659547.
Orphanet Report Series. Prevalence of rare diseases: Bibliographic data. Orphanet Report Series, Rare Diseases collection. November 2024. ORPHA:753 Purine nucleoside phosphorylase deficiency. Available at: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=753